Regeneron Pharmaceuticals Inc. agreed to pay Fujifilm Diosynth Biotechnologies more than $3 billion over the next decade to ...

Biotech giant Regeneron Pharmaceuticals, Inc. REGN is slated to report first-quarter 2025 results on April 29, 2025. The ...

With that in mind, let's consider two stocks down 17% and 36%, respectively, this year that are worth investing in right now: Regeneron Pharmaceuticals ( REGN 0.40%) and Moderna ( MRNA -0.79%).

Baird lowered the firm’s price target on Regeneron (REGN) to $652 from $759 and keeps a Neutral rating on the shares. The firm said its Eylea ...

FUJIFILM has invested about $4 billion in building biopharmaceutical manufacturing sites and life sciences capabilities.

Regeneron Pharmaceuticals has a 52-week low of $525.99 and a 52-week high of $1,211.20. The firm has a market capitalization of $65.57 billion, a PE ratio of 15.67, a price-to-earnings-growth ...

The top 20 biopharmas demonstrated a strong start to 2025, despite ongoing uncertainty surrounding Trump’s tariffs.

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced a significant expansion of its manufacturing capacity through a new agreement with FUJIFILM Diosynth Biotechnologies (“Fujifilm ...

Swiss drugmaker Roche will spend $50B to expand its U.S. manufacturing, while New York-based Regeneron will spend more than ...

Regeneron Pharmaceuticals has entered a new manufacturing and supply agreement with Fujifilm Diosynth Biotechnologies.

Sanofi signed a deal with Earendil Labs for $125 million upfront and $1.72 billion in milestone payments. Regeneron Pharmaceuticals signed a deal worth more than $3 billion with contract drug ...

Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician ...